Independent research-peptide intelligence
Check the
certificate.
Then choose
the vendor.
We grade research peptides by published evidence. We record what public registers say about vendors, and the date we read them. Every claim links to its source.
How we grade the evidence. Read our editorial policy.
Vendor directory · sourced from public registers
Registered companies
8995
Sites
6
Segments
0
Scores
- 30
- Peptide profiles, each one cited
- 4
- Regulatory regions in the tracker
- 136
- Linked primary sources
Every vendor score links to a public COA. If we cannot see the certificate, we do not score the vendor.
We publish sources,
not scores.
This directory holds 89 companies across 95 registered sites. For each one we record what a public register says and the date we read it. We do not score a company, and we do not rank companies. A score would be our opinion dressed as a measurement, and you could not check it.
- 01
503B outsourcing facilities
Facilities registered with the FDA to compound medicines in batches.
86 - 02
503A compounding pharmacies
Pharmacies that compound a medicine for one named patient.
0 - 03
Telehealth providers
Services that connect a patient to a prescriber online.
0 - 04
Online research suppliers
Sellers of research chemicals. No registry lists them.
3 - 05
International laboratories
Testing laboratories outside the United States.
0 - 06
Contract manufacturers
Companies that manufacture medicines for other companies.
20
The thesis
A vendor earns trust by making itself auditable. If you can't verify a claim, it's marketing.
We anchor every score to publicly verifiable certificates of analysis — batch-matched, third-party, method-disclosed.
Three evidence grades.
No hype.
Emerging
Early preclinical work. Limited data, or no independent replication.
Moderate
A large preclinical body. Some human data.
Established
Strong human clinical evidence.
Each profile lists its sources with a PubMed or ClinicalTrials.gov link. You can read the study yourself.
Metabolic
Semaglutide
Semaglutide is a GLP-1 receptor agonist. The FDA approves it for type 2 diabetes, chronic weight management, and cardiovascular risk reduction.
Metabolic
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist. The FDA approved it on 13 May 2022.
Metabolic
Retatrutide
Retatrutide is an investigational triple receptor agonist. No regulator approves it. The Phase 3 TRIUMPH program is now reporting results.
Metabolic
AOD-9604
AOD-9604 is a modified growth hormone fragment. Six human trials ran. The Phase 2B trial failed its endpoint.
Metabolic
HGH Fragment 176-191
HGH Fragment 176-191 is a growth hormone fragment with animal data only. No human trial tested it.
Same molecule.
Different rules.
We track the status of each compound by region, and we link every row to the regulator that published it.
NowThe FDA Pharmacy Compounding Advisory Committee reviewed BPC-157, TB-500, KPV and MOTS-c on 23 July 2026. We track the outcome.
- Approved
Semaglutide
The FDA approves semaglutide as a prescription medicine. The FDA declared the shortage resolved on 21 February 2025. Enforcement discretion for 503A pharmacies ended on 22 April 2025 and for 503B facilities on 22 May 2025. On 30 April 2026 the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List.
- Approved
Tesamorelin
The FDA approves tesamorelin for one clinical indication. Any other use falls outside the approval.
- Research-only
BPC-157
The FDA placed BPC-157 in Category 2 in 2023. A 503A pharmacy cannot compound it. The Pharmacy Compounding Advisory Committee reviewed it on 23 July 2026 for the 503A Bulks List. WADA names BPC-157 under S0 and prohibits it at all times.
- Research-only
TB-500
No FDA approval. The Pharmacy Compounding Advisory Committee reviewed TB-500 on 23 July 2026 for wound healing. WADA prohibits it in sport.
- Research-only
Ipamorelin
No FDA approval. The FDA placed ipamorelin acetate in Category 2. WADA prohibits it in sport.
FREE - ONE EMAIL A WEEK
What changed in the evidence this week.
New trial results, FDA and WADA status changes, and vendor records we updated - with the primary source linked next to every line. No protocols, no dosing, no product pitches.
Tools · lab arithmetic
Do the arithmetic
before you handle the vial.
Use the Reconstitution Calculator to find concentration and draw volume. Use the Stack Builder to see the evidence spread across a set of compounds. These tools do laboratory arithmetic. They do not give a dose and they are not medical advice.